Global Epidemiology, Amgen Inc., Thousand Oaks, CA 91320, United States.
Eur J Intern Med. 2010 Feb;21(1):12-6. doi: 10.1016/j.ejim.2009.10.003. Epub 2009 Nov 3.
The extent and magnitude of mortality risk among patients splenectomised for a variety of indications is not well-described in the literature. We assessed mortality risk among splenectomised patients compared to the general population and to un-splenectomised patients with similar underlying medical conditions.
We conducted a historical population-based cohort study in Denmark between January 1, 1996 and December 31, 2005. Mortality risk was evaluated within 90 days, 91-365 days, and >365 days post-splenectomy, controlling for age, sex, and comorbid conditions using Cox proportional hazards models for a splenectomised cohort compared to the general Danish population and a matched indication cohort.
We identified a total of 3812 splenectomised patients, 38,120 population comparisons, and 8310 matched indication comparisons. Within 90 days post-splenectomy, the adjusted relative risk (RR) for death, regardless of indication, was highly elevated compared to the general population: RR 33.6 [95% confidence interval (CI): 6.9, 35.0]. This risk declined substantially after 90 days post-splenectomy but remained higher 365 days post-splenectomy for all indications compared to the general population. When compared to the matched indication cohort, short- and long-term mortality risk with splenectomy was not increased.
Regardless of indication, the adjusted short- and long-term risk of death for splenectomised patients was higher than the general population. Most of this risk seems to be due to the underlying splenectomy indication and not to splenectomy alone.
各种适应证行脾切除术患者的死亡率范围和程度在文献中尚未得到充分描述。我们评估了脾切除术患者与普通人群以及具有相似基础医疗条件但未行脾切除术患者的死亡率风险。
我们在丹麦进行了一项基于人群的历史队列研究,时间范围为 1996 年 1 月 1 日至 2005 年 12 月 31 日。使用 Cox 比例风险模型,通过比较脾切除术患者队列与普通丹麦人群和具有匹配适应证的队列,评估脾切除术患者术后 90 天内、91-365 天内和>365 天内的死亡率风险,同时控制年龄、性别和合并症。
我们共确定了 3812 例脾切除术患者、38120 例人群对照和 8310 例匹配适应证对照。脾切除术患者术后 90 天内,无论适应证如何,死亡的调整相对风险(RR)均显著高于普通人群:RR 33.6[95%置信区间(CI):6.9,35.0]。脾切除术 90 天后,死亡风险显著下降,但所有适应证患者术后 365 天的死亡风险仍高于普通人群。与匹配适应证队列相比,脾切除术患者的短期和长期死亡率风险并未增加。
无论适应证如何,脾切除术患者的调整后短期和长期死亡风险均高于普通人群。这种风险主要归因于脾切除术的适应证,而非脾切除术本身。